T. Rowe Price Investment Management, Inc. Centessa Pharmaceuticals PLC Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,753,248 shares of CNTA stock, worth $22.4 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,753,248
Previous 3,418,600
48.71%
Holding current value
$22.4 Million
Previous $57.3 Million
55.97%
% of portfolio
0.02%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding CNTA
# of Institutions
142Shares Held
124MCall Options Held
163KPut Options Held
816K-
Medicxi Ventures Management (Jersey) LTD20MShares$255 Million75.25% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$127 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$123 Million4.7% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.95MShares$88.7 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X05.92MShares$75.5 Million0.05% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.2B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...